Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
Crossref DOI link: https://doi.org/10.1007/s11060-014-1636-6
Published Online: 2014-10-29
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wen, Qiuting
Jalilian, Laleh
Lupo, Janine M.
Molinaro, Annette M.
Chang, Susan M.
Clarke, Jennifer
Prados, Michael
Nelson, Sarah J.
License valid from 2014-10-29